Kira Pharmaceuticals
5 known investors
Kira Pharmaceuticals develops therapies targeting the complement system for patients with complement-mediated autoimmune and inflammatory diseases across areas including hematology, nephrology, neurology, dermatology and ophthalmology. It uses a proprietary LOGIC drug discovery platform and has a lead asset entering Phase 2 alongside additional pipeline assets.
BiotechHealthtech
Investors · 5
Foresite CapitalLarkspur
Quan CapitalShanghai
Vivo CapitalPalo Alto · $10M – $50M
Ikarian CapitalreportedDallas
Also in the syndicate · 1
Affinity Asset Advisorslead
In the news
Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition | Quiver Quantitativequiverquant.com · Aug 2026
Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidatesblockonomi.com · Aug 2026Frequently asked questions
- What does Kira Pharmaceuticals do?
- Kira Pharmaceuticals develops therapies targeting the complement system for patients with complement-mediated autoimmune and inflammatory diseases across areas including hematology, nephrology, neurology, dermatology and ophthalmology. It uses a proprietary LOGIC drug discovery platform and has a lead asset entering Phase 2 alongside additional pipeline assets.
- Who are Kira Pharmaceuticals's investors?
- Kira Pharmaceuticals's investors include Foresite Capital, Quan Capital, Vivo Capital, Ikarian Capital.